Nasus Pharma Ltd.·Healthcare
Recent Phase 2 topline results demonstrate NS002's potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study planned for Q4 2026
In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study evaluating NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis.
The Phase 2 study results indicated that NS002 has the potential to exceed EpiPen performance, demonstrating statistically significant improvements in the time to therapeutic threshold.
NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% of subjects receiving NS002 reached the threshold compared to 64.6% with EpiPen®
TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that members of the Company's management will host a conference call and webcast on Monday, March 16, 2026, at 8:00 a.m.
TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced that Company management will participate and present at the upcoming virtual Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com during March 11-12, 2026.
